Trial Profile
A Phase 1, Non-Randomized, Open-Label, Single-Dose, Single Period Study With Non-Pharmacologically Active Dose Of Pf-06427878 To Characterize Pharmacokinetics Following Intravenous Administration In Healthy, Adult, Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Aug 2020
Price :
$35
*
At a glance
- Drugs PF 6427878 (Primary)
- Indications Hyperlipidaemia
- Focus Pharmacokinetics
- Sponsors Pfizer
- 17 Dec 2014 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
- 29 Oct 2014 Planned End Date changed from 30 Nov 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
- 16 Sep 2014 New trial record